Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients

Biological Psychiatry

Volumn 56, Issue 6, 2004, Pages 418-426

  Carpenter, Linda L ^a,b   Moreno, Francisco A ^c   Kling, Mitchel A ^d   Anderson, George M ^e   Regenold, William T ^d   Labiner, David M ^c   Price, Lawrence H ^a,b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebrospinal fluid; depression; GABA; mechanism; monoamines; neurotransmitters; norepinephrine; vagus nerve stimulation

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DEXAMPHETAMINE; FLUOXETINE; GABAPENTIN; HYDROXYZINE; LAMOTRIGINE; METHYLPHENIDATE; MIRTAZAPINE; NALTREXONE; NEFAZODONE; NORADRENALIN; OLANZAPINE; PAROXETINE; QUETIAPINE; SERTRALINE; THYROID HORMONE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VAGUS NERVE; VAGUS NERVE STIMULATION;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; ELECTRIC STIMULATION THERAPY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MASS SPECTROMETRY; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; NOREPINEPHRINE; SPINAL PUNCTURE; TIME FACTORS; VAGUS NERVE;

EID: 4444316743     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.06.025     Document Type: Article

References (54)

1. M. Altemus, S.E. Swedo, H.L. Leonard, D. Richter, D.R. Rubinow, W.Z Potter Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine Arch Gen Psychiatry 51 1994 794 803
2. R. Armitage, M. Husain, R. Hoffmann, A.J. Rush The effects of vagus nerve stimulation on sleep EEG in depression. A preliminary report J Psychosom Res 54 2003 475 482
3. J. Backman, C. Alling, M. Alsen, G. Regnell, L. Traskman-Bendz Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment Eur Neuropsychopharmacol 10 2000 341 349
4. E. Ben-Menachem, A. Hamberger, T. Hedner, E.J. Hammond, B.M. Uthman, J Slater Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures Epilepsy Res 20 1995 221 227
5. E. Ben-Menachem, R. Manon-Espaillat, R. Ristanovic, B.J. Wilder, H. Stefan, W Mirza Vagus nerve stimulation for treatment of partial seizures 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group Epilepsia 35 1994 616 626
6. D.E. Bohning, M.P. Lomarev, S. Denslow, Z. Nahas, A. Shastri, M.S. George Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI Invest Radiol 36 2001 470 479
7. C.L. Bowden, S.H. Koslow, I. Hanin, J.W. Maas, J.M. Davis, E. Robins Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid Clin Pharmacol Ther 37 1985 316 324
8. L.L. Carpenter, G.M. Anderson, J.M. Siniscalchi, P.B. Chappell, L.H. Price Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans Neuropsychopharmacology 28 2003 339 347
9. L.L. Carpenter, G.R. Heninger, R.T. Malison, A.R. Tyrka, L.H. Price Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression J Affect Disord 79 2004 285 289
10. L.L. Carpenter, G.R. Heninger, C.J. McDougle, A.R. Tyrka, C.N. Epperson, L.H. Price Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania Psychiatry Res 112 2002 257 262
11. L.L. Carpenter, A.R. Tyrka, C.J. McDougle, R.T. Malison, M.J. Owens, C.B Nemeroff Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects Neuropsychopharmacology 29 2004 777 784
12. J. Chotai, R. Adolfsson Converging evidence suggests that monoamine neurotransmitter turnover in human adults is associated with their season of birth Eur Arch Psychiatry Clin Neurosci 252 2002 130 134
13. J. Cohen Statistical Power Analysis for the Behavioral Sciences 2nd ed 1988 Lawrence Erlbaum Hillsdale, New Jersey
14. D. Cremniter, S. Jamain, K. Kollenbach, J.C. Alvarez, Y. Lecrubier, A Gilton CSF 5-HIAA levels are lower in impulsive as compared to nonimpulsive violent suicide attempters and control subjects Biol Psychiatry 45 1999 1572 1579
15. M.D. De Bellis, T.D. Geracioti, M. Altemus, M.A. Kling Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers Biol Psychiatry 33 1993 636 641
16. M.D. De Bellis, P.W. Gold, T.D. Geracioti, S.J. Listwak, M.A. Kling Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am J Psychiatry 150 1993 656 657
17. G. Engstrom, C. Alling, K. Blennow, G. Regnell, L. Traskman-Bendz Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls Eur Neuropsychopharmacol 9 1999 399 405
18. M.S. George, A.J. Rush, H.A. Sackeim, L.B. Marangell Vagus nerve stimulation (VNS): Utility in neuropsychiatric disorders Int J Neuropsychopharmacol 6 2003 73 83
19. Goodwin FK, Jamison KR (1990): Biochemical and pharmacological studies. Manic-Depressive Illness. New York: Oxford University Press, 416-502.
20. W. Guy ECDEU Assessment Manual 1976 National Institute of Mental Health Rockville, Maryland
21. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
22. A. Handforth, C.M. DeGiorgio, S.C. Schachter, B.M. Uthman, D.K. Naritoku, E.S Tecoma Vagus nerve stimulation therapy for partial-onset seizures A randomized active-control trial Neurology 51 1998 48 55
23. T.R. Henry, R.A. Bakay, J.R. Votaw, P.B. Pennell, C.M. Epstein, T.L Faber Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy I. Acute effects at high and low levels of stimulation Epilepsia 39 1998 983 990
24. J.K. Hsiao, H. Agren, J.J. Bartko, M.V. Rudorfer, M. Linnoila, W.Z. Potter Monoamine neurotransmitter interactions and the prediction of antidepressant response Arch Gen Psychiatry 44 1987 1078 1083
25. J.R. Kaplan, S.B. Manuck, M.B. Fontenot, J.J. Mann Central nervous system monoamine correlates of social dominance in cynomolgus monkeys (Macaca fascicularis) Neuropsychopharmacology 26 2002 431 443
26. S.E. Krahl, K.B. Clark, D.C. Smith, R.A. Browning Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation Epilepsia 39 1998 709 714
27. J.F. Leckman, W.K. Goodman, G.M. Anderson, M.A. Riddle, P.B. Chappell, M.T McSwiggan-Hardin Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls Neuropsychopharmacology 12 1995 73 86
28. J.T. Little, T.A. Ketter, A.A. Mathe, M.A. Frye, D. Luckenbaugh, R.M. Post Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression Biol Psychiatry 45 1999 285 289
29. M. Lomarev, S. Denslow, Z. Nahas, J.H. Chae, M.S. George, D.E. Bohning Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency/dose dependent effects J Psychiatr Res 36 2002 219 227
30. L.B. Marangell, A.J. Rush, M.S. George, H.A. Sackeim, C.R. Johnson, M.M Husain Vagus nerve stimulation (VNS) for major depressive episodes One year outcomes Biol Psychiatry 51 2002 280 287
31. B. Martensson, S. Nyberg, G. Toresson, E. Brodin, L. Bertilsson Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid Acta Psychiatr Scand 79 1989 586 596
32. G.L. Morris, W.M. Mueller Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05 Neurology 53 1999 1731 1735
33. D.K. Naritoku, W.J. Terry, R.H. Helfert Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve Epilepsy Res 22 1995 53 62
34. R.M. Post, F.K. Goodwin Approaches to brain amines in psychiatric patients: A reevaluation of cerebrospinal fluid studies L.L. Iversen S.D. Iversen S.H. Snyder Handbook of Psychopharmacology, Volume 13: Biology of Mood and Antianxiety Drugs 1978 Plenum Press New York 147 185 editors
35. W.Z. Potter, M. Scheinin, R.N. Golden, M.V. Rudorfer, R.W. Cowdry, H.M Calil Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites Arch Gen Psychiatry 42 1985 1171 1177
36. E.D. Risby, J.K. Hsiao, T. Sunderland, H. Agren, M.V. Rudorfer, W.Z. Potter The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio Clin Pharmacol Ther 42 1987 547 554
37. A. Roy, J. Berman, R. Williams, C. Kuhn, B. Gonzalez Higher levels of CSF homovanillic acid in recently abstinent cocaine-dependent patients Am J Psychiatry 159 2002 1053 1055
38. M.V. Rudorfer, H.K. Manji, W.Z. Potter Monoaminergic actions of ECT Clin Neuropharmacol 15 suppl 1 pt A 1992 677A 678A
39. M.V. Rudorfer, E.D. Risby, J.K. Hsiao, M. Linnoila, W.Z. Potter Disparate biochemical actions of electroconvulsive therapy and antidepressant drugs Convuls Ther 4 1988 133 140
40. M.V. Rudorfer, E.D. Risby, J.K. Hsiao, M. Linnoila, W.Z. Potter ECT alters human monoamines in a different manner from that of antidepressant drugs Psychopharmacol Bull 24 1988 396 399
41. A.J. Rush, M.S. George, H.A. Sackeim, L.B. Marangell, M.M. Husain, C Giller Vagus nerve stimulation (VNS) for treatment-resistant depressions A multicenter study Biol Psychiatry 47 2000 276 286
42. H.A. Sackeim, J.G. Keilp, A.J. Rush, M.S. George, L.B. Marangell, J.S Dormer The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression Neuropsychiatry Neuropsychol Behav Neurol 14 2001 53 62
43. H.A. Sackeim, A.J. Rush, M.S. George, L.B. Marangell, M.M. Husain, Z Nahas Vagus nerve stimulation (VNS) for treatment-resistant depression Efficacy, side effects, and predictors of outcome Neuropsychopharmacology 25 2001 713 728
44. M.C. Salinsky, B.M. Uthman, R.K. Ristanovic, J.F. Wernicke, W.B. Tarver Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group Arch Neurol 53 1996 1176 1180
45. S.C. Schachter Vagus nerve stimulation therapy summary Five years after FDA approval Neurology 59 2002 S15 S20
46. M. Scheinin Monoamine metabolites in human cerebrospinal fluid Indicators of neuronal activity? Med Biol 63 1985 1 17
47. Y. Sheline, M.E. Bardgett, J.G. Csernansky Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors J Clin Psychopharmacol 17 1997 11 14
48. L. Sher, M.A. Oquendo, S. Li, Y.Y. Huang, M.F. Grunebaum, A.K Burke Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism Neuropsychopharmacology 28 2003 1712 1719
49. H. Shimamoto, K. Takasaki, M. Shigemori, T. Imaizumi, M. Ayabe, H. Shoji Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease J Neurol 248 suppl 3II 2001 I48 I52
50. H. Soderstrom, K. Blennow, A.K. Sjodin, A. Forsman New evidence for an association between the CSF HVA 5-HIAA ratio and psychopathic traits J Neurol Neurosurg Psychiatry 74 2003 918 921
51. E.A. Struys, W.S. Guerand, H.J. ten Brink, C. Jakobs Combined method for the determination of gamma-aminobutyric acid and beta-alanine in cerebrospinal fluid by stable isotope dilution mass spectrometry J Chromatogr B Biomed Sci Appl 732 1999 245 249
52. G.J. Ter Horst, C. Streetland Ascending projections of the solitary tract nucleus I. Robin A. Barraco Nucleus of the Solitary Tract 1994 CRC Press London
53. K. Vonck, K. Van Laere, S. Dedeurwaerdere, J. Caemaert, J. De Reuck, P. Boon The mechanism of action of vagus nerve stimulation for refractory epilepsy The current status J Clin Neurophysiol 18 2001 394 401
54. B.R. Walker, A. Easton, K. Gale Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius Epilepsia 40 1999 1051 1057